ResearcherAmsterdam UMC Location University of AmsterdamNo recent work listed
Sil Kordes
Matched on ORCID iD 0000-0002-9796-1734; OpenAlex author ID A5044963215. Sources: OpenAlex.
Their work
- Papers
- 3
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 5
2013: 1 paper · 2014: none · 2015: 2 papers
Papers 3
- Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. Co-author DOI 10.1007/s00280-015-2730-y↗
- Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Co-author DOI 10.1016/s1470-2045(15)00027-3↗
- A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and capecitabine in patients with advanced panc… Co-author DOI 10.1007/s10637-012-9802-1↗
Closest collaborators
The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Dick J. Richel · 3 shared papers, 2013–2015 · strength 0.15
- Paper Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. DOI 10.1007/s00280-015-2730-y↗
- Paper Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. DOI 10.1016/s1470-2045(15)00027-3↗
- Paper A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and cap… DOI 10.1007/s10637-012-9802-1↗
- Johanna W. Wilmink · 3 shared papers, 2013–2015 · strength 0.15
- Paper Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. DOI 10.1007/s00280-015-2730-y↗
- Paper Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. DOI 10.1016/s1470-2045(15)00027-3↗
- Paper A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and cap… DOI 10.1007/s10637-012-9802-1↗
- Heinz‐Josef Klümpen · 2 shared papers, 2013–2015 · strength 0.10
- Paper Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer. DOI 10.1007/s00280-015-2730-y↗
- Paper A phase I/II, non-randomized, feasibility/safety and efficacy study of the combination of everolimus, cetuximab and cap… DOI 10.1007/s10637-012-9802-1↗
- Jan H.M. Schellens · 1 shared paper, 2015 · strength 0.06
- Michaël Pollak · 1 shared paper, 2015 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.